PHAXIAM Therapeutics
formed in 2023 from Pherecydes' merger with Erytech, PHAXIAM aimed to build a 35-45-phage GMP bank covering the most critical resistant pathogens by end-2026, with commercial IV and orthopedic-infection programs.…
- Country
- France
Discontinued
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.